Relay Therapeutics (RLAY)
(Real Time Quote from BATS)
$7.65 USD
-0.34 (-4.26%)
Updated Aug 2, 2024 10:31 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Relay Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 750 | 999 | 958 | 678 | 356 |
Receivables | 0 | 0 | 0 | 75 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 20 | 20 | 18 | 17 | 5 |
Total Current Assets | 770 | 1,020 | 976 | 770 | 361 |
Net Property & Equipment | 11 | 12 | 7 | 6 | 8 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 2 | 2 | 2 | 0 | 0 |
Deposits & Other Assets | 3 | 3 | 3 | 1 | 1 |
Total Assets | 844 | 1,100 | 1,008 | 800 | 393 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 11 | 8 | 6 | 7 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 23 | 14 | 6 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 26 | 0 | 0 | 0 |
Total Current Liabilities | 30 | 64 | 24 | 14 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 13 | 32 | 65 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 538 |
Total Liabilities | 92 | 150 | 111 | 37 | 574 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 2,153 | 2,019 | 1,667 | 1,167 | 9 |
Retained Earnings | -1,401 | -1,059 | -768 | -404 | -189 |
Other Equity | 0 | -10 | -1 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 752 | 950 | 898 | 763 | -180 |
Total Liabilities & Shareholder's Equity | 844 | 1,100 | 1,008 | 800 | 393 |
Total Common Equity | 752 | 950 | 898 | 763 | -180 |
Shares Outstanding | 127.40 | 120.90 | 108.00 | 89.90 | NA |
Book Value Per Share | 5.90 | 7.86 | 8.31 | 8.49 | 0.00 |
Fiscal Year End for Relay Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 750 | 750 | 811 | 872 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 20 | 20 | 21 | 13 |
Total Current Assets | NA | 770 | 770 | 832 | 884 |
Net Property & Equipment | NA | 10 | 11 | 11 | 12 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 2 | 2 | 2 | 2 |
Deposits & Other Assets | NA | 3 | 3 | 3 | 3 |
Total Assets | NA | 841 | 844 | 907 | 962 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 8 | 9 | 13 | 15 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 22 | 15 | 31 | 27 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2 | 1 | 1 | 25 |
Total Current Liabilities | NA | 37 | 30 | 51 | 72 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 13 | 28 | 29 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 96 | 92 | 129 | 152 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 2,229 | 2,153 | 2,099 | 2,067 |
Retained Earnings | NA | -1,482 | -1,401 | -1,317 | -1,251 |
Other Equity | NA | -1 | 0 | -3 | -6 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 746 | 752 | 778 | 810 |
Total Liabilities & Shareholder's Equity | NA | 841 | 844 | 907 | 962 |
Total Common Equity | 0 | 746 | 752 | 778 | 810 |
Shares Outstanding | 132.70 | 132.70 | 127.40 | 123.20 | 121.60 |
Book Value Per Share | 0.00 | 5.62 | 5.90 | 6.32 | 6.66 |